PHARMACOLOGICAL CORRECTION OF IMMUNE DISORDERS IN PATIENTS WITH CHRONIC HEART FAILURE AND ISCHEMIC HEART DISEASE
Currently, there are few data on the effect of cardiovascular drugs on the immune status of patients with heart failure (HF). This paper provides information on the impact of ß-adrenergic blocking agent (BAB), angiotensin-converting enzyme inhibitors (ACEI) on the maintenance of markers of immune inflammation in the blood, as well as on inhibition of synthesis of tumor necrosis factor-α (TNF-α) and on blocking of interaction between TNF-α and membrane receptors.
Osipova OA, Drapkina OM, Kulikovskii VF, et al. Pharmacological correction of immune disorders in patients with chronic heart failure and ischemic heart disease. Research Result. Medicine and Pharmacy Series. 2015;1(4):19-24 (In Russian). DOI: 10.18413 / 2313-8955-2015-1-4-19-24
While nobody left any comments to this publication.
You can be first.
I.M. Sechenov MMU, 2004.
cardiosclerosis / Osipova O.A., Vlasenko O.A.// Scientific journal of Belgorod State University. Series: Medicine. Pharmacy. 2011. Vol. 14. No.10. Pp. 77-80.
European Journal of Natural History. 2014. № 5. Р. 31-32.